Ironwood Pharmaceuticals (NASDAQ:IRWD) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Ironwood Pharmaceuticals (NASDAQ:IRWD) released its earnings results on Thursday. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01), FiscalAI reports. The company had revenue of $113.04 million during the quarter, compared to analysts’ expectations of $114.84 million. Ironwood Pharmaceuticals had a net margin of 33.36% and a negative return on equity of 58.38%.

Here are the key takeaways from Ironwood Pharmaceuticals’ conference call:

• LINZESS delivered strong momentum: Q2 U.S. net sales rose 14% year over year to $282.3 million, supported by mid-single-digit prescription growth and improved net pricing. Ironwood raised its 2026 LINZESS sales outlook to $1.15 billion–$1.20 billion, implying growth of more than 30% and a return to blockbuster status.
• The FDA approved LINZESS for functional constipation in pediatric patients aged two and older, making it the only prescription therapy approved for this age group and expanding the brand’s addressable patient population.
• Ironwood initiated active enrollment in the confirmatory Phase III STARS-2 trial for apraglutide in short bowel syndrome with intestinal failure. Management believes the once-weekly therapy’s efficacy, tolerability, and potential to reduce parenteral-support dependence could support a best-in-class profile, though enrollment remains an execution priority.
• Q2 GAAP net income was $51 million and adjusted EBITDA was $83 million; full-year revenue guidance increased to $460 million–$485 million and adjusted EBITDA guidance to above $310 million. The company repaid $200 million of convertible notes and expects gross debt below $300 million and leverage below 1x by year-end.
• R&D spending is expected to rise in the second half as STARS-2 enrollment and site activation ramp, with modestly higher SG&A also anticipated. The ultimate expense increase will depend on how quickly additional trial sites are brought online.

Ironwood Pharmaceuticals Price Performance

IRWD stock traded up $0.06 during midday trading on Friday, reaching $4.32. 1,842,560 shares of the company’s stock traded hands, compared to its average volume of 2,179,845. The company has a market capitalization of $704.41 million, a P/E ratio of 5.61 and a beta of 0.20. Ironwood Pharmaceuticals has a fifty-two week low of $0.81 and a fifty-two week high of $5.78. The business has a 50-day moving average price of $3.90 and a two-hundred day moving average price of $3.97.

Insider Activity at Ironwood Pharmaceuticals

In related news, insider Ronald Silver sold 127,890 shares of Ironwood Pharmaceuticals stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total transaction of $578,062.80. Following the transaction, the insider owned 313,680 shares in the company, valued at approximately $1,417,833.60. The trade was a 28.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Julie Mchugh sold 21,571 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $3.73, for a total transaction of $80,459.83. Following the sale, the director directly owned 250,749 shares of the company’s stock, valued at approximately $935,293.77. This trade represents a 7.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 9.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Jump Financial LLC purchased a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter worth about $34,000. Cibc World Markets Corp purchased a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter valued at about $36,000. Evolve Private Wealth LLC acquired a new position in Ironwood Pharmaceuticals during the 4th quarter worth approximately $50,000. Abel Hall LLC acquired a new position in Ironwood Pharmaceuticals during the 4th quarter worth approximately $56,000. Finally, Integrated Wealth Concepts LLC boosted its holdings in Ironwood Pharmaceuticals by 21.4% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 3,406 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on IRWD. Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Wall Street Zen downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $6.23.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.